Analysts Lift AstraZeneca 2026 Revenue Estimate to $46.52B and EPS to $6.07
Analysts project AstraZeneca’s Q1 2026 revenue at $11.04 billion and earnings at $1.44 per share ahead of its April 29 release. Full-year 2026 revenue estimates have climbed to $46.52 billion with EPS at $6.07, while one-year price targets average $163.64, implying a 17.1% upside.
1. Q1 2026 Revenue and EPS Estimates
Analysts forecast AstraZeneca will post Q1 2026 revenue of $11.04 billion and EPS of $1.44 per share in its April 29 release.
2. Full-Year 2026 and 2027 Estimate Revisions
Over the past 90 days, full-year 2026 revenue estimates have risen from $45.96 billion to $46.52 billion and EPS forecasts from $5.92 to $6.07, while 2027 revenue and EPS estimates have climbed to $49.56 billion and $7.06 respectively.
3. Analyst Price Targets and Recommendations
Twenty-two analysts set an average one-year price target of $163.64, ranging from $112.73 to $204.52, implying a 17.1% upside, while brokerage firms maintain an average 2.0 rating, indicating an Outperform stance.